Reznikov M, Blackmore T K, Finlay-Jones J J, Gordon D L
Department of Microbiology and Infectious Diseases, Flinders Medical Centre, Bedford Park, Australia.
Eur J Clin Microbiol Infect Dis. 1995 Jan;14(1):58-61. doi: 10.1007/BF02112622.
Nasopharyngeal aspirates and throat swab specimens were compared in a polymerase chain reaction (PCR)-based test for Mycoplasma pneumoniae. The pathogen was detected in 50% and 45% of throat swab specimens and aspirates, respectively. However, in specimens negative for Mycoplasma pneumoniae by PCR, amplification inhibitors were detected in 0% and 36% of throat specimens and aspirates, respectively. Further investigations confirmed that no throat specimens, but one-quarter of aspirates, are likely to be rejected for containing inadequate respiratory material or excess amplification inhibitors. Because rejection of most of the unsuitable specimens is possible only after PCR, the use of aspirates is less cost-effective. This, and the reluctance to subject patients to aspiration, make the aspirate an inferior specimen for detection of Mycoplasma pneumoniae by PCR.
在基于聚合酶链反应（PCR）的肺炎支原体检测中，对鼻咽抽吸物和咽拭子标本进行了比较。在咽拭子标本和抽吸物中，肺炎支原体病原体的检测率分别为50%和45%。然而，在PCR检测肺炎支原体呈阴性的标本中，咽拭子标本和抽吸物中分别有0%和36%检测到扩增抑制剂。进一步调查证实，没有咽拭子标本，但四分之一的抽吸物可能因呼吸道材料不足或扩增抑制剂过量而被拒收。由于大多数不合适的标本只有在PCR后才有可能被拒收，因此使用抽吸物的成本效益较低。此外，由于不愿让患者接受抽吸，使得抽吸物成为通过PCR检测肺炎支原体的劣质标本。
